156 related articles for article (PubMed ID: 2041574)
1. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
Petru E; Schmähl D
Neoplasma; 1991; 38(2):147-55. PubMed ID: 2041574
[TBL] [Abstract][Full Text] [Related]
2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
3. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
5. [Second tumor following Hodgkin's disease].
Schmitt K; Tulzer W
Padiatr Padol; 1984; 19(3):259-62. PubMed ID: 6548008
[TBL] [Abstract][Full Text] [Related]
6. Second malignancy complicating Hodgkin's disease.
Tawil E; Mercier JP
J Can Assoc Radiol; 1983 Jun; 34(2):108-13. PubMed ID: 6688422
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin's disease, splenectomy and secondary leukemia.
Centurioni R; Brianzoni F; Leoni P; Danieli G
Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
[No Abstract] [Full Text] [Related]
8. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's disease and acute leukemia. Is it a true association?
Avilés A; Díaz-Maqueo JC; Ayala JR; Cortés HD; García EL
Arch Med Res; 1992; 23(1):65-8. PubMed ID: 1308794
[TBL] [Abstract][Full Text] [Related]
10. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
11. [Acute leukemias and solid tumors in the course of Hodgkin disease].
Jacquillat C; Auclerc G; Weil M; Auclerc MF; Maral J
Bull Cancer; 1983; 70(1):61-6. PubMed ID: 6687694
[TBL] [Abstract][Full Text] [Related]
12. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
[TBL] [Abstract][Full Text] [Related]
13. [Acute myeloid leukemia after treatment of Hodgkin's disease].
Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
[TBL] [Abstract][Full Text] [Related]
14. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
15. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
16. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
17. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
Klimo P; Connors JM
Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
[TBL] [Abstract][Full Text] [Related]
18. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
19. [Acute leukemia in patients treated for Hodgkin's disease].
Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
[No Abstract] [Full Text] [Related]
20. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
